MedWatch

Novo: It’s time to make up lost ground

Through two negotiation rounds Novo Nordisk has managed to secure a higher price in Japan for the insulin product Tresiba compared with rival drug Lantus.

Foto: Novo Nordisk/PR

4 % may not sound like much, but the price premium that Novo Nordisk won for its long-acting basal insulin Tresiba compared with Sanofi’s Lantus is quite significant, as it has been won on the Japanese market.

“On the surface of it 4 % does not sound like much, but it is not half bad for Novo Nordisk. You should keep in mind that it is the fourth basal insulin approved in Japan, and it is difficult to win price premiums in Japan. To me, this price premium is very good. In fact, only 3 out of 43 approved drugs in 2012 achieved a higher price than comparable drugs. Tresiba is among those three,” says Sydbank-analyst Søren Løntoft Hansen.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Eli Lilly får forlomme til fedmehåb hos FDA

Med en fast track status får medicinalselskabet Eli Lilly sænket behandlingstiden for sin registreringsansøgning hos FDA af lægemiddelhåbet Tirzepatid til omtrent seks måneder fra de normale ca. 10 måneder.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier